Trial · NCT03334721
Gabapentin for Bipolar & Cannabis Use Disorders
NCT03334721, Phase 2, Completed, Medical University of South Carolina; results first posted 2020-11-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Gabapentin for Bipolar & Cannabis Use Disorders. Trials, record NCT03334721. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03334721
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Gabapentin for Bipolar & Cannabis Use Disorders
- NCT number
- NCT03334721
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 23 participants, actual
- Lead sponsor
- Medical University of South Carolina
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Cannabis Use Disorder, Substance Use Disorders
- Interventions
- Gabapentin, Placebo Oral Capsule
- First posted
- 2017-11-07
- Last updated
- 2020-11-13
- Results first posted
- 2020-11-13
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Prefrontal GABA Concentrations Through Proton Magnetic Resonance Spectroscopy | Day 5 of each experimental condition | Concentrations of GABA, normalized to water and corrected for CSF%, in dorsal anterior cingulate measured via Proton Magnetic Resonance Spectroscopy. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Prefrontal GABA Concentrations Through Proton Magnetic Resonance Spectroscopy | Day 5 of each experimental condition | Individuals with Bipolar Disorder and Cannabis Use Disorder | Institutional Units | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Prefrontal GABA Concentrations Through Proton Magnetic Resonance Spectroscopy | Gabapentin | GABA (randomization order 1, gabapentin 1st) | 2.625 | Standard Deviation 0.324 | Institutional Units |
| Prefrontal GABA Concentrations Through Proton Magnetic Resonance Spectroscopy | Placebo Oral Capsule | GABA (randomization order 1, gabapentin 1st) | 2.696 | Standard Deviation 0.313 | Institutional Units |
| Prefrontal GABA Concentrations Through Proton Magnetic Resonance Spectroscopy | Gabapentin | GABA (randomization order 2, placebo 1st) | 2.609 | Standard Deviation 0.290 | Institutional Units |
| Prefrontal GABA Concentrations Through Proton Magnetic Resonance Spectroscopy | Placebo Oral Capsule | GABA (randomization order 2, placebo 1st) | 2.720 | Standard Deviation 0.248 | Institutional Units |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Gabapentin, Then Placebo Oral Capsule | 12 | |
| Overall Study | STARTED | Placebo Oral Capsule, Then Gabapentin | 11 | |
| Overall Study | COMPLETED | Gabapentin, Then Placebo Oral Capsule | 10 | |
| Overall Study | COMPLETED | Placebo Oral Capsule, Then Gabapentin | 11 | |
| Overall Study | NOT COMPLETED | Gabapentin, Then Placebo Oral Capsule | 2 | |
| Overall Study | NOT COMPLETED | Placebo Oral Capsule, Then Gabapentin | 0 |
Source ClinicalTrials.gov
Adverse events24
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Gabapentin | 1 | 23 | 1 |
| other | Nausea | Gastrointestinal disorders | Placebo Oral Capsule | 1 | 22 | 1 |
| other | Vomiting | Gastrointestinal disorders | Gabapentin | 1 | 23 | 1 |
| other | Vomiting | Gastrointestinal disorders | Placebo Oral Capsule | 0 | 22 | 0 |
| other | Diarrhea | Gastrointestinal disorders | Gabapentin | 0 | 23 | 0 |
| other | Diarrhea | Gastrointestinal disorders | Placebo Oral Capsule | 1 | 22 | 1 |
| other | Fatigue | General disorders | Gabapentin | 4 | 23 | 4 |
| other | Fatigue | General disorders | Placebo Oral Capsule | 0 | 22 | 0 |
| other | Dizziness | Nervous system disorders | Gabapentin | 2 | 23 | 2 |
| other | Dizziness | Nervous system disorders | Placebo Oral Capsule | 0 | 22 | 0 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Gabapentin | 0 | 23 |
| Total, all-cause mortality | Placebo Oral Capsule | 0 | 22 |
| Total, other adverse events | Gabapentin | 8 | 23 |
| Total, other adverse events | Placebo Oral Capsule | 6 | 22 |
| Total, serious adverse events | Gabapentin | 0 | 23 |
| Total, serious adverse events | Placebo Oral Capsule | 0 | 22 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34390300 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Gabapentin vs Placebo Oral Capsule: deaths from any cause | Trial comparisons |
| Gabapentin vs Placebo Oral Capsule: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03334721
GET https://conductscience.org/api/trials/v1/NCT03334721/events?page=2